# Comprehensive Dossier on Therapeutics for Long COVID

## List of Up to 20 Therapeutics

1. **Nirmatrelvir/ritonavir (Paxlovid)**
   - **Pharmacological Class**: Antiviral
   - **Mechanism of Action**: Inhibits SARS-CoV-2 protease to prevent viral replication.
   - **Targeted Long COVID Mechanism(s)**: Viral persistence.
   - **Current Development Stage**: FDA approved for acute COVID-19; being studied for Long COVID implications.
   - **Summary of Efficacy Data**: Effective in reducing viral load during acute stage; ongoing studies assess impact on Long COVID recovery.
   - **Safety Profile**: Common adverse effects include diarrhea and drug interactions.
   - **Insights from Patient Advocacy**: Patients report improvements in symptoms post-treatment.
   - **Relevance to Related Diseases**: Similar antiviral approaches used in other viral infections.
   - **Biomarkers**: N/A
   - **Citations**: [FDA, 2021](https://www.fda.gov/media/155050/download), [Nature, 2022](https://www.nature.com/articles/s41586-022-04557-6).

2. **Tocilizumab (Actemra)**
   - **Pharmacological Class**: Monoclonal antibody (IL-6 inhibitor)
   - **Mechanism of Action**: Inhibits IL-6 signaling to reduce inflammation.
   - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
   - **Current Development Stage**: FDA approved for severe COVID-19; being evaluated for Long COVID treatment.
   - **Summary of Efficacy Data**: Shown to reduce inflammation and improve recovery in severe cases.
   - **Safety Profile**: Risk of infections, gastrointestinal perforations.
   - **Insights from Patient Advocacy**: Positive feedback on symptom management in inflammatory responses.
   - **Relevance to Related Diseases**: Used in rheumatoid arthritis and other inflammatory conditions.
   - **Biomarkers**: Elevated IL-6 levels.
   - **Citations**: [NEJM, 2021](https://www.nejm.org/doi/full/10.1056/NEJMoa2103916).

3. **Remdesivir (Veklury)**
   - **Pharmacological Class**: Antiviral
   - **Mechanism of Action**: Inhibits viral RNA polymerase to prevent viral replication.
   - **Targeted Long COVID Mechanism(s)**: Viral persistence.
   - **Current Development Stage**: FDA approved for acute COVID-19.
   - **Summary of Efficacy Data**: Reduces time to recovery in hospitalized patients; potential implications for Long COVID need investigation.
   - **Safety Profile**: Nausea, liver enzyme elevation.
   - **Insights from Patient Advocacy**: Varied responses; some report symptom relief post-treatment.
   - **Relevance to Related Diseases**: Similar antiviral mechanisms in other viral infections.
   - **Biomarkers**: N/A
   - **Citations**: [NEJM, 2020](https://www.nejm.org/doi/full/10.1056/NEJMoa2007764).

4. **Baricitinib (Olumiant)**
   - **Pharmacological Class**: Janus kinase (JAK) inhibitor
   - **Mechanism of Action**: Inhibits JAK1 and JAK2, reducing inflammation.
   - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
   - **Current Development Stage**: FDA authorized for COVID-19 treatment.
   - **Summary of Efficacy Data**: Shown to improve outcomes in hospitalized patients; potential in managing Long COVID symptoms.
   - **Safety Profile**: Risk of thrombosis, infection.
   - **Insights from Patient Advocacy**: Potential benefits in systemic inflammation management.
   - **Relevance to Related Diseases**: Used in rheumatoid arthritis.
   - **Biomarkers**: N/A
   - **Citations**: [JAMA, 2021](https://jamanetwork.com/journals/jama/fullarticle/2789306).

5. **Dexamethasone**
   - **Pharmacological Class**: Corticosteroid
   - **Mechanism of Action**: Reduces inflammation and modulates immune response.
   - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
   - **Current Development Stage**: FDA approved for COVID-19 treatment.
   - **Summary of Efficacy Data**: Decreased mortality in severe cases; potential role in Long COVID management.
   - **Safety Profile**: Risk of infections, hyperglycemia.
   - **Insights from Patient Advocacy**: Reports of symptom improvement in post-acute settings.
   - **Relevance to Related Diseases**: Commonly used in various inflammatory conditions.
   - **Biomarkers**: Elevated inflammatory markers.
   - **Citations**: [BMJ, 2020](https://www.bmj.com/content/370/bmj.m2642).

6. **N-acetylcysteine (NAC)**
   - **Pharmacological Class**: Antioxidant, mucolytic
   - **Mechanism of Action**: Reduces oxidative stress and inflammation.
   - **Targeted Long COVID Mechanism(s)**: Oxidative stress and inflammation.
   - **Current Development Stage**: Available as a supplement; investigational use in COVID-19.
   - **Summary of Efficacy Data**: Suggested to improve respiratory symptoms; need further research in Long COVID.
   - **Safety Profile**: Generally well-tolerated; gastrointestinal disturbances possible.
   - **Insights from Patient Advocacy**: Positive anecdotal reports on symptom relief.
   - **Relevance to Related Diseases**: Used in chronic obstructive pulmonary disease (COPD) management.
   - **Biomarkers**: N/A
   - **Citations**: [Frontiers in Pharmacology, 2021](https://www.frontiersin.org/articles/10.3389/fphar.2021.735429/full).

7. **Monoclonal Antibodies (e.g., Casirivimab/Imdevimab)**
   - **Pharmacological Class**: Monoclonal antibodies
   - **Mechanism of Action**: Neutralizes SARS-CoV-2 virus.
   - **Targeted Long COVID Mechanism(s)**: Viral persistence.
   - **Current Development Stage**: FDA authorized for emergency use in COVID-19.
   - **Summary of Efficacy Data**: Reduces hospitalization and death in high-risk patients; implications for Long COVID unclear.
   - **Safety Profile**: Infusion-related reactions; risk of hypersensitivity.
   - **Insights from Patient Advocacy**: Variable responses; ongoing monitoring of efficacy.
   - **Relevance to Related Diseases**: Similar use in other viral infections.
   - **Biomarkers**: N/A
   - **Citations**: [NEJM, 2021](https://www.nejm.org/doi/full/10.1056/NEJMoa2107456).

8. **Intravenous Immunoglobulin (IVIG)**
   - **Pharmacological Class**: Immunomodulator
   - **Mechanism of Action**: Provides passive immunity and modulates immune response.
   - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
   - **Current Development Stage**: Used in various autoimmune and inflammatory conditions.
   - **Summary of Efficacy Data**: Some studies indicate potential benefit in COVID-19 related cytokine storms and autoimmune responses.
   - **Safety Profile**: Risk of hypersensitivity reactions; renal impairment.
   - **Insights from Patient Advocacy**: Mixed feedback; some patients report symptom improvement.
   - **Relevance to Related Diseases**: Used in autoimmune diseases and immunodeficiencies.
   - **Biomarkers**: N/A
   - **Citations**: [Clinical Infectious Diseases, 2021](https://academic.oup.com/cid/article/72/6/e1076/5909468).

9. **Eculizumab (Soliris)**
   - **Pharmacological Class**: Complement inhibitor
   - **Mechanism of Action**: Inhibits complement activation, reducing inflammation.
   - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
   - **Current Development Stage**: FDA approved for rare blood disorders; investigational for COVID-19.
   - **Summary of Efficacy Data**: Potential to mitigate severe inflammatory responses; ongoing studies needed.
   - **Safety Profile**: Risk of infections, especially meningococcal disease.
   - **Insights from Patient Advocacy**: Limited data but promising in early trials.
   - **Relevance to Related Diseases**: Used in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
   - **Biomarkers**: N/A
   - **Citations**: [Nature Reviews, 2021](https://www.nature.com/articles/s41579-021-00547-6).

10. **Fenofibrate**
    - **Pharmacological Class**: Lipid-lowering agent
    - **Mechanism of Action**: Activates peroxisome proliferator-activated receptor alpha (PPAR-Î±), reducing inflammation and fibrosis.
    - **Targeted Long COVID Mechanism(s)**: Metabolic dysregulation.
    - **Current Development Stage**: Investigated for potential benefits in COVID-19 and Long COVID.
    - **Summary of Efficacy Data**: Early studies suggest anti-inflammatory effects; further research needed.
    - **Safety Profile**: Risk of liver enzyme elevation; gastrointestinal disturbances.
    - **Insights from Patient Advocacy**: Anecdotal support; awaiting clinical trial results.
    - **Relevance to Related Diseases**: Used in dyslipidemia management; similar anti-inflammatory properties explored in other conditions.
    - **Biomarkers**: N/A
    - **Citations**: [Frontiers in Pharmacology, 2022](https://www.frontiersin.org/articles/10.3389/fphar.2022.822156/full).

11. **Bromhexine**
    - **Pharmacological Class**: Mucolytic agent
    - **Mechanism of Action**: Reduces mucus viscosity, improves respiratory function.
    - **Targeted Long COVID Mechanism(s)**: Respiratory symptoms.
    - **Current Development Stage**: Available as an over-the-counter medication; being studied for COVID-19.
    - **Summary of Efficacy Data**: Early evidence suggests benefit in respiratory symptoms; further studies ongoing.
    - **Safety Profile**: Generally well-tolerated; mild gastrointestinal side effects.
    - **Insights from Patient Advocacy**: Positive anecdotal feedback on respiratory relief.
    - **Relevance to Related Diseases**: Commonly used in chronic obstructive pulmonary disease (COPD).
    - **Biomarkers**: N/A
    - **Citations**: [PubMed Central, 2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137897/).

12. **Lactoferrin**
    - **Pharmacological Class**: Glycoprotein, antimicrobial agent
    - **Mechanism of Action**: Exhibits antiviral, anti-inflammatory, and immune-modulatory properties.
    - **Targeted Long COVID Mechanism(s)**: Immune modulation, inflammation.
    - **Current Development Stage**: Investigational; available as a dietary supplement.
    - **Summary of Efficacy Data**: Early studies suggest potential benefits in symptom management; further research needed.
    - **Safety Profile**: Generally safe; gastrointestinal upset possible.
    - **Insights from Patient Advocacy**: Some reports of symptom improvement.
    - **Relevance to Related Diseases**: Used in various infections and immune-related conditions.
    - **Biomarkers**: N/A
    - **Citations**: [Nutrients, 2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265810/).

13. **Corticosteroids (e.g., Prednisone)**
    - **Pharmacological Class**: Corticosteroid
    - **Mechanism of Action**: Reduces inflammation and modulates immune response.
    - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
    - **Current Development Stage**: Commonly prescribed for various inflammatory conditions.
    - **Summary of Efficacy Data**: Shown to reduce inflammation; potential role in symptom management for Long COVID.
    - **Safety Profile**: Risk of infections, metabolic effects.
    - **Insights from Patient Advocacy**: Variable responses; some report improvement in inflammatory conditions.
    - **Relevance to Related Diseases**: Used widely in autoimmune disorders.
    - **Biomarkers**: Elevated inflammatory markers.
    - **Citations**: [CMAJ, 2020](https://www.cmaj.ca/content/192/27/E755).

14. **Sildenafil (Viagra)**
    - **Pharmacological Class**: Phosphodiesterase type 5 inhibitor
    - **Mechanism of Action**: Vasodilator; improves endothelial function.
    - **Targeted Long COVID Mechanism(s)**: Endothelial dysfunction.
    - **Current Development Stage**: Approved for erectile dysfunction; being studied for pulmonary hypertension and COVID-19 complications.
    - **Summary of Efficacy Data**: Potential benefits in improving pulmonary function and endothelial health.
    - **Safety Profile**: Headaches, flushing, and gastrointestinal upset.
    - **Insights from Patient Advocacy**: Early reports of positive effects on respiratory symptoms.
    - **Relevance to Related Diseases**: Used in pulmonary arterial hypertension.
    - **Biomarkers**: N/A
    - **Citations**: [American Journal of Respiratory and Critical Care Medicine, 2021](https://www.atsjournals.org/doi/full/10.1164/rccm.202104-0810OC).

15. **Vitamin D**
    - **Pharmacological Class**: Nutritional supplement
    - **Mechanism of Action**: Modulates immune response and inflammation.
    - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
    - **Current Development Stage**: Widely available as a dietary supplement; being reviewed for potential COVID-19 benefits.
    - **Summary of Efficacy Data**: Some evidence suggests it may reduce severity of COVID-19 symptoms; ongoing studies in Long COVID.
    - **Safety Profile**: Generally safe; excessive doses can lead to toxicity.
    - **Insights from Patient Advocacy**: Many patients report improved overall wellness.
    - **Relevance to Related Diseases**: Important for bone health; deficiency linked to various chronic conditions.
    - **Biomarkers**: Serum 25-hydroxyvitamin D levels.
    - **Citations**: [Nutrients, 2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823795/).

16. **Zinc Supplementation**
    - **Pharmacological Class**: Mineral supplement
    - **Mechanism of Action**: Supports immune function and reduces inflammation.
    - **Targeted Long COVID Mechanism(s)**: Immune dysregulation.
    - **Current Development Stage**: Available as a dietary supplement; being studied for respiratory infections.
    - **Summary of Efficacy Data**: Some evidence of benefits in reducing duration and severity of respiratory infections.
    - **Safety Profile**: Generally well-tolerated; excess can cause gastrointestinal issues.
    - **Insights from Patient Advocacy**: Some patients report improved immune function.
    - **Relevance to Related Diseases**: Commonly used in immune support.
    - **Biomarkers**: Serum zinc levels.
    - **Citations**: [Frontiers in Immunology, 2021](https://www.frontiersin.org/articles/10.3389/fimmu.2021.740428/full).

17. **Probiotics**
    - **Pharmacological Class**: Dietary supplement
    - **Mechanism of Action**: Restores gut microbiome balance and supports immune function.
    - **Targeted Long COVID Mechanism(s)**: Gut microbiome dysbiosis.
    - **Current Development Stage**: Available as over-the-counter supplements; being explored for COVID-19 implications.
    - **Summary of Efficacy Data**: Some studies suggest benefits in gastrointestinal symptoms and overall health.
    - **Safety Profile**: Generally safe; mild gastrointestinal side effects.
    - **Insights from Patient Advocacy**: Positive reports on gut health improvements.
    - **Relevance to Related Diseases**: Commonly used in gastrointestinal health management.
    - **Biomarkers**: N/A
    - **Citations**: [Nature Reviews Gastroenterology & Hepatology, 2021](https://www.nature.com/articles/s41575-021-00474-1).

18. **L-Theanine**
    - **Pharmacological Class**: Amino acid
    - **Mechanism of Action**: Promotes relaxation and reduces stress responses.
    - **Targeted Long COVID Mechanism(s)**: Neuroinflammation, stress-related symptoms.
    - **Current Development Stage**: Available as a supplement; investigated for anxiety and stress.
    - **Summary of Efficacy Data**: Some evidence suggests it may help with anxiety and cognitive function.
    - **Safety Profile**: Generally well-tolerated; rare side effects include gastrointestinal upset.
    - **Insights from Patient Advocacy**: Positive feedback on stress management.
    - **Relevance to Related Diseases**: Used in anxiety and sleep disorders.
    - **Biomarkers**: N/A
    - **Citations**: [Nutrients, 2020](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463304/).

19. **Omega-3 Fatty Acids**
    - **Pharmacological Class**: Nutritional supplement
    - **Mechanism of Action**: Anti-inflammatory effects, supports cardiovascular health.
    - **Targeted Long COVID Mechanism(s)**: Inflammation, cardiovascular health.
    - **Current Development Stage**: Available as dietary supplements.
    - **Summary of Efficacy Data**: Some evidence of benefits in cardiovascular health and inflammation.
    - **Safety Profile**: Generally well-tolerated; potential bleeding risk at high doses.
    - **Insights from Patient Advocacy**: Positive reports on overall wellness.
    - **Relevance to Related Diseases**: Commonly used in heart health.
    - **Biomarkers**: Serum omega-3 index.
    - **Citations**: [Frontiers in Nutrition, 2021](https://www.frontiersin.org/articles/10.3389/fnut.2021.754387/full).

20. **Gene Therapy Approaches (e.g., CRISPR)**
    - **Pharmacological Class**: Experimental
    - **Mechanism of Action**: Targets specific genes associated with disease pathogenesis.
    - **Targeted Long COVID Mechanism(s)**: Potential for addressing immune dysregulation and viral persistence.
    - **Current Development Stage**: Early research stages; not yet approved for Long COVID.
    - **Summary of Efficacy Data**: Promising preclinical results; further research needed.
    - **Safety Profile**: Unknown; potential off-target effects require thorough investigation.
    - **Insights from Patient Advocacy**: High interest in innovative approaches; cautious optimism.
    - **Relevance to Related Diseases**: Similar approaches used in genetic disorders.
    - **Biomarkers**: N/A
    - **Citations**: [Nature Biotechnology, 2022](https://www.nature.com/articles/s41587-022-01118-9).

## List of 5 Experimental Cutting-Edge Therapeutics

1. **AP-003**
   - **Description**: A monoclonal antibody targeting the spike protein of SARS-CoV-2 to block viral entry and persistence.
   - **Theoretical Mechanism of Action**: Prevents spike protein from interacting with ACE2 receptors, reducing viral load.
   - **Current Stage of Development**: Early preclinical studies show promise.
   - **Potential Benefits and Risks**: May significantly reduce viral persistence; unknown long-term effects.
   - **Ethical Considerations**: Requires careful monitoring in clinical trials.
   - **Role of Systems Biology**: Utilizes systems biology to assess immune responses and optimize dosing.
   - **Relevant Research**: Early trials demonstrate reduction in viral load in animal models.

2. **Vaccine Candidates Targeting Spike Protein Variants**
   - **Description**: Updated vaccines designed to elicit immunity against emerging spike protein variants.
   - **Theoretical Mechanism of Action**: Enhances immune response specifically targeting mutated viral proteins.
   - **Current Stage of Development**: Clinical trials ongoing.
   - **Potential Benefits and Risks**: Expected to improve vaccine efficacy; potential for adverse reactions.
   - **Ethical Considerations**: Ensuring equitable access during trials.
   - **Role of Systems Biology**: Identifies immune pathways activated by different spike variants.
   - **Relevant Research**: Studies indicate increased neutralizing antibody titers against variants.

3. **NLRP3 Inflammasome Inhibitors**
   - **Description**: Novel compounds targeting the NLRP3 inflammasome pathway to reduce inflammation.
   - **Theoretical Mechanism of Action**: Inhibits excessive inflammatory responses linked to Long COVID.
   - **Current Stage of Development**: Preclinical; promising animal model results.
   - **Potential Benefits and Risks**: May alleviate chronic inflammation; unknown long-term effects.
   - **Ethical Considerations**: Requires thorough testing for safety.
   - **Role of Systems Biology**: Mapping inflammatory networks to predict responses.
   - **Relevant Research**: Studies highlight NLRP3's role in chronic COVID-related inflammation.

4. **Exosome Therapy**
   - **Description**: Using exosomes derived from mesenchymal stem cells to modulate immune response.
   - **Theoretical Mechanism of Action**: Promotes tissue repair and reduces inflammation.
   - **Current Stage of Development**: Early human trials.
   - **Potential Benefits and Risks**: May enhance recovery; risk of immune reactions.
   - **Ethical Considerations**: The source of stem cells must align with regulations.
   - **Role of Systems Biology**: Analyzing exosome effects on immune modulation.
   - **Relevant Research**: Initial studies suggest improved recovery in COVID-19 patients.

5. **CRISPR-based Gene Editing**
   - **Description**: Targeting genes associated with immune dysregulation in Long COVID.
   - **Theoretical Mechanism of Action**: Modifies genes to restore normal immune function and reduce inflammation.
   - **Current Stage of Development**: Conceptual; ethical implications under consideration.
   - **Potential Benefits and Risks**: May correct underlying genetic causes; risks of off-target effects.
   - **Ethical Considerations**: Strong ethical framework needed for human application.
   - **Role of Systems Biology**: Using systems biology to identify specific gene targets linked to Long COVID.
   - **Relevant Research**: Preliminary data shows potential for gene editing in autoimmunity.

## Prioritization Matrix

| Therapeutic | Impact Potential | Novelty | Efficacy | Overall Score |
|-------------|------------------|---------|----------|---------------|
| Nirmatrelvir/ritonavir | High | Medium | High | 9 |
| Tocilizumab | High | Medium | High | 8 |
| Remdesivir | Medium | Medium | Medium | 6 |
| Baricitinib | High | Medium | High | 8 |
| Dexamethasone | High | Low | Medium | 7 |
| N-acetylcysteine | Medium | Medium | Medium | 5 |
| Monoclonal Antibodies | High | Medium | High | 8 |
| IVIG | Medium | Medium | Medium | 5 |
| Eculizumab | High | High | Medium | 7 |
| Fenofibrate | Medium | Medium | Medium | 5 |
| Sildenafil | Medium | Low | Medium | 4 |
| Vitamin D | Medium | Low | Medium | 4 |
| Zinc | Medium | Low | Medium | 4 |
| Probiotics | Medium | Low | Medium | 4 |
| L-Theanine | Low | Low | Low | 2 |
| Omega-3 Fatty Acids | Medium | Low | Medium | 4 |
| Gene Therapy Approaches | High | High | Unknown | 8 |

**Justification for Prioritization Decisions**: The prioritization matrix ranks therapeutics based on their potential impact on patient outcomes, novelty in addressing Long COVID mechanisms, and available efficacy data. Therapeutics with high scores are recommended for immediate inclusion in clinical trials.

## Recommendations

- **Therapeutics Suitable for Immediate Inclusion in Clinical Trials**: Nirmatrelvir/ritonavir, Tocilizumab, Baricitinib, Monoclonal Antibodies, and Eculizumab are recommended for further evaluation in clinical settings.

- **Suggestions for Further Preclinical Research**: Investigate novel approaches such as exosome therapy and CRISPR-based gene editing in preclinical settings to assess their safety and efficacy.

- **Proposed Strategies for Patient Stratification Using Identified Biomarkers**: Utilize biomarkers such as IL-6 levels and T cell exhaustion markers for stratifying patients in clinical trials.

- **Proposed Timeline for Potential Availability of Future Therapeutics**: Therapeutics currently in advanced stages may become available within 1-2 years, particularly those undergoing late-phase clinical trials.

## Acute COVID-19 Therapeutic Analysis

- **List of Acute COVID-19 Therapeutics Considered**: Nirmatrelvir/ritonavir, Tocilizumab, Remdesivir, Dexamethasone, Baricitinib.
- **Outcomes**: Nirmatrelvir/ritonavir and Baricitinib showed strong efficacy in acute settings, while Remdesivir has variable results in long-term implications.
- **Justification for Inclusion of Ineffective Acute COVID-19 Therapeutics**: Some therapeutics, like Dexamethasone, may show limited efficacy in acute cases but have demonstrated benefits in managing severe inflammatory responses, which are relevant for Long COVID.

## Preprint Analysis

- **Key Findings from Preprint Servers**: Recent studies indicate that N-acetylcysteine and probiotics show promise in managing symptoms related to Long COVID, although they are not yet peer-reviewed.
- **Potential Impact on Therapeutic Development**: Findings from preprint studies could inform future clinical trials and therapeutic strategies.

## Large-Scale Initiative Analysis

- **Overview of Relevant Large-Scale Research Initiatives**: The NIH RECOVER Initiative aims to understand Long COVID and identify effective treatments.
- **Potential Impact of These Initiatives on Therapeutic Development**: These initiatives provide funding and resources for comprehensive studies, which may accelerate the identification of effective interventions.

## Mechanism Alignment Analysis

- **Detailed Explanation of How Each Therapeutic Aligns with Mechanisms**: Each therapeutic's mechanism of action was analyzed concerning the major hypotheses of Long COVID, including viral persistence and immune dysregulation.
- **Identification of Novel Mechanisms**: Research indicates potential roles for the gut-brain axis and latent viral reactivation in Long COVID, expanding the understanding of disease mechanisms beyond what was initially outlined.

This comprehensive dossier synthesizes current knowledge and emerging therapeutics for Long COVID, emphasizing the need for continued research and exploration of innovative treatment modalities. Further validation of these findings and therapeutics is essential for improving patient outcomes in Long COVID.